BioCryst Pharmaceuticals (NASDAQ:BCRX) executives used an appearance at the Bank of America Healthcare Conference to outline the company’s strategy around its hereditary angioedema franchise, recent business development activity and key pipeline milestones.
Babar Ghias, BioCryst’s chief financial officer, described the company as being at “a phenomenal inflection point,” citing continued momentum for ORLADEYO, the company’s oral therapy for hereditary angioedema, or HAE. Ghias said BioCryst’s goal is to build “a high-growth, innovative rare disease biotech with multiple products on the market by 2030.”
ORLADEYO Remains Central to Growth Strategy
According to Ghias, BioCryst would need to add an average of about 150 net patients per year through 2029 to reach that target. He said the company has historically added more than 200 net patients annually and continues to see new prescribers in the sixth year of launch.
The company also discussed pediatric use of ORLADEYO. Ghias said BioCryst received pediatric approval last year and is the only oral formulation approved for patients ages two and older. He said the pediatric market was not a meaningful part of the company’s $625 million to $645 million guidance because BioCryst expected the shift toward prophylactic use in children to take time.
Pediatric Supply Issue Described as Isolated Quality Matter
BioCryst also addressed a supply disruption involving ORLADEYO granules. Ghias said the issue was not related to safety, efficacy or the FDA, but instead was “a very isolated quality batch release issue” identified late in the process before shipment.
Ghias said the company is working on root cause analysis and expects to provide more information in the second quarter. In the meantime, he said prescriptions are being received and BioCryst’s patient services team is beginning insurance verification and other background work so patients can be converted once supply is available.
Astria Acquisition Expands HAE Pipeline
BioCryst executives also discussed the acquisition of Astria Therapeutics and its HAE candidate navenibart. Ghias said the deal made strategic sense because BioCryst already has the only oral HAE prophylaxis product on the market and could potentially add a best-in-class injectable therapy using the same commercial infrastructure.
Sandeep Menon, BioCryst’s chief research and development officer, said navenibart is being studied as an infrequently dosed injectable therapy. He highlighted the potential for once-every-three-month dosing, with a possible six-month regimen also under study, and said the company believes the profile could offer convenience, fewer injection site reactions and a mechanism closely tied to the disease.
Ghias said market research suggests three-month dosing is a key threshold for patients and physicians. He described the potential shift from 12 to 24 injections per year with existing products to four or possibly two injections per year as meaningful.
BioCryst said the navenibart Phase III program remains on track for enrollment by midyear. Menon said the company expects to file a biologics license application at the end of next year, with top-line data around that timeframe, while BioCryst continues discussions with the FDA regarding data disclosure and requirements for the six-month dosing arm.
Menon said the Phase II study showed attack-rate reductions of roughly 90% to 92%, but cautioned against focusing solely on point estimates. He said physicians and patients would also consider convenience, safety, injection site reactions and overall clinical benefit.
Executives Address Competitive Landscape
Asked about competition from another potential oral HAE therapy, Ghias said the market is not “winner-takes-all.” He said patients who are well controlled on ORLADEYO may have limited reason to switch to another once-daily pill, while acknowledging that BioCryst expects competition for new patient starts.
Menon added that real-world data suggest patients on ORLADEYO can achieve what he described as a functionally low attack rate, supported by years of safety experience. He said prescribers may be reluctant to change therapy for patients who are already controlled.
On gene editing and gene therapy approaches in HAE, Menon said he remains “mixed” for this indication because patients already have multiple treatment options. He said such therapies would need to show more than functional control and would carry expectations around long-term safety.
Netherton Syndrome Program and Business Development
BioCryst also highlighted its Netherton syndrome program, which targets KLK5. Menon said the company has shown in healthy volunteers that the drug reaches the areas of interest in the skin and is now moving into a proof-of-concept study in patients. He said the 12-patient study is on track to deliver results by the end of the year.
Ghias said the Netherton study is not especially expensive, though he noted there is some manufacturing work associated with the fusion protein. He said BioCryst wants proof of clinical activity before committing to a larger investment.
On future business development, Ghias said BioCryst views itself as a broad rare disease company rather than solely an HAE company. He said the company is more interested in later-stage opportunities that could support its goal of having multiple products by 2030, while avoiding added near-term risk. He also said capital allocation options could include business development and potentially share buybacks as the company generates cash.
About BioCryst Pharmaceuticals (NASDAQ:BCRX)
BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.
The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.
